drugset
drugset / Trial / NCT06405633

A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD

NCT06405633 ↗

Phase 1/2 Active not recruiting 24 enrolled Wave Life Sciences USA, Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this open-label study is to assess the safety, tolerability, pharmacodynamics, and pharmacokinetics of WVE-006 in participants with alpha-1 antitrypsin deficiency (AATD) following Period 1 single ascending dose (SAD) and Period 2 multiple ascending doses (MAD), respectively.

Timeline

Start
2024-07-19
Primary completion
2026-09
Completion
2026-09

Drugs

EvaluationDrugModalityDoseRoute
Subject WVE-006 Oligonucleotide (other) — —

Indications

alpha 1-antitrypsin deficiency